NCT06183645Recruiting
Exploratory Study on Predicting CIDP Patients' Decline During IV Immunoglobulin Treatment Adaptation Feasibility.
ActiCIDP : Exploratory Study on the Feasibility of Predicting CIDP Patients' Evolution Decline During Intravenous Immunoglobulins Treatment Adaptation.
Source: ClinicalTrials.gov · Last updated 12 Feb 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
ActiCIDP is a monocentric academic study. Patients with Chronic inflammatory demyelinating polyradiculoneuritis may be included on a voluntary basis. The investigators plan to include a group of approximately 40 patients with CIDP. The investigators have planned to assess patient every three months for a year. After each visit, participants will wear Actimyo for one month daily.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 40 (estimated)
- First submitted
- 14 Dec 2023
- Start date
- 28 Aug 2023
- Primary completion date
- Jan 2028
- Lead sponsor
- Centre Hospitalier Universitaire de Liege
- NCT number
- NCT06183645
What you commit to
- Study type: Observational
- Planned participants: 40
- From 28 Aug 2023 to the primary completion date, Jan 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Surgery or serious traumatic injury ≤ 6 months
- Anti-myeline antibodies (anti-MAG) positive or nodo-paranodopathy
Other illness
- Significant cognitive or communication disorders
- Other autoimmune disease that requires Corticosteroids, IVIg, Plasma Exchange treatment
- Any other condition that, according to the investigator, could significantly interfere with patient evaluation or safety.
Other
- Non ambulant patient
- Current participation to a therapeutic trial
- Pregnancy or breastfeeding
Who the study is looking for
- Diagnosed with CIDP or possible CIDP based on 2021 EAN/PNS criteria2.
- Treated with IVIg (≤1g/kg/3-8week)
- Clinically Stable disease for 3 months (according to treating physician opinion).
- No treatment withdrawal failure within 1 year
- Age over 18 years
Age in the registry: 18 years to 99 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CHR Citadelle Coordinator of this site? Confirm its status | Liège | Belgium | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.